Rezolute, Inc. (RZLT) News
Follow Rezolute, Inc. (RZLT) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 20 public stories across 10 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Rezolute completes enrollment in Phase 3 upLIFT study
Rezolute announced completion of enrollment in its Phase 3 upLIFT study of ersodetug in tumor hyperinsulinism.
EQUITY | Oct 14, 2026, 08:05 PM UTC
M
Rezolute (RZLT) Gains FDA Nod for Pre-BLA Meeting on Pancreatic Disorder Therapy
Rezolute (RZLT) received a positive regulatory update from the FDA for its therapy targeting a rare genetic disorder of the pancreas, potentially advancing it towards an official filing. The shares saw an initial jump of
EQUITY | Oct 05, 2026, 12:59 PM UTC
M
Rezolute Receives FDA Recommendation for Pre-BLA Meeting
Rezolute has been recommended by the FDA to hold a Pre-Biologics License Application (BLA) meeting. This meeting is a precursor to submitting a BLA for its treatment for congenital hyperinsulinism. The agency reaffirmed
EQUITY | Oct 05, 2026, 11:01 AM UTC
H
Why Vicor Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Shares of Vicor Corp (NASDAQ: VICR ) rose sharply in pre-market trading after the company raised its third-quarter sequential revenue growth guidance. Vicor raised its third-quarter sequential revenue growth guidance to
LIVE | Oct 01, 2026, 08:31 AM UTC
L
Rezolute Raised to Buy From Hold by Craig-Hallum
Ratings actions from Benzinga: GMT) Rezolute Price Target Raised to $7.00/Share From $4.00 by Craig-HallumRatings actions from Benzinga
NEWS | Sep 29, 2026, 12:42 PM UTC
L
Weekly Recap: sunRIZE Phase 3 failure and No revenue, FY2026 loss
Rezolute, Inc. (NASDAQ:RZLT) said its Phase 3 sunRIZE in congenital hyperinsulinism missed the primary endpoint but submitted extra analyses and awaits FDA feedback, while ENDO 2026 data showed promising response in tumo
EARNINGS | Sep 28, 2026, 11:03 AM UTC
L
Rezolute Is Maintained at Buy by HC Wainwright & Co.
Ratings actions from Benzinga
NEWS | Sep 25, 2026, 04:23 PM UTC
L
HC Wainwright & Co. maintains Buy rating on Rezolute, $10 price target
HC Wainwright & Co. maintained their Buy rating on Rezolute's stock with a price target of $10.00.The price target implies an upside of 153.8% from the Sep 24 close of $3.94.Key takeaways from the analyst noteStrong Pipe
EQUITY | Sep 25, 2026, 04:12 PM UTC
L
Rezolute, Inc. FY 2026: Revenue $0 Net loss $77.6M, EPS $(0.75) — 10-K Summary
Rezolute, Inc. reported fiscal 2026 results as a clinical-stage company with no product revenue: Revenue was $0 and the company posted a net loss of $77.6M, or $(0.75) diluted EPS, compared with a net loss of $74.4M and
EARNINGS | Sep 24, 2026, 08:36 PM UTC
L
Rezolute reports FY2026 net loss $77.6M, cash and investments $107.8M as of June 30, 2026
Rezolute reported a net loss of $77.6 million for fiscal year 2026 and $20.5 million for the fourth quarter ended June 30, 2026, with cash, cash equivalents and marketable securities totaling $107.8 million at year-end.
EARNINGS | Sep 24, 2026, 08:24 PM UTC
L
Rezolute Q4 net loss narrows as R&D expenses fall
OverviewOutlookResult DriversCompany press release:Key DetailsAnalyst CoverageReuters Recommended ReadsFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feed
EARNINGS | Sep 24, 2026, 08:14 PM UTC
L
Rezolute, Inc. (RZLT) Posts FY26 Net Loss $77.6M; Cash $107.8M
Rezolute reported cash, cash equivalents and marketable securities of $107.8M at June 30, 2026, R&D of $53.8M, G&A of $29.2M, and a FY26 net loss of $77.6M. Q4 FY26 net loss was $20.5M.Material DetailsContext by AI Analy
EARNINGS | Sep 24, 2026, 08:11 PM UTC
L
Rezolute Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business Update
REDWOOD CITY, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. NASDAQ:RZLT (“Rezolute” or the “Company”), a late-stage ultra-rare rare disease company focused on treating refractory hypoglycemia caused by any fo
EARNINGS | Sep 24, 2026, 08:11 PM UTC
L
Rezolute 4Q Loss/Shr 20c >RZLT
Rezolute 4Q Loss/Shr 20c >RZLT
NEWS | Sep 24, 2026, 08:07 PM UTC
L
BRIEF-Rezolute Q4 EPS USD -0.2
Sep 24 (Reuters) - Rezolute Q4 operating expenses USD 21.562 million.
EARNINGS | Sep 24, 2026, 08:06 PM UTC
M
Rezolute reports Q4 and full-year fiscal 2026 results
Rezolute reported fourth-quarter and full-year fiscal 2026 financial results and provided a business update.
EQUITY | Sep 24, 2026, 08:06 PM UTC
H
Rezolute, Inc. expected to post a loss of 15 cents a share - Earnings Preview
Previous quarterly performance (using preferred earnings measure in US dollars). This summary was machine generated September 11 at 20:04 GMT. All figures in US dollars unless otherwise stated. (For questions concerning
EARNINGS | Sep 11, 2026, 08:04 PM UTC
L
Rezolute provides FDA review update for Phase 3 sunRIZE study
Rezolute says it has provided an update on the FDA review of its Phase 3 sunRIZE study results in congenital hyperinsulinism.
REGULATION | Sep 09, 2026, 11:03 AM UTC
L
Rezolute to participate in upcoming investor conferences
Rezolute said management plans to participate in upcoming investor conferences.
EQUITY | Sep 02, 2026, 11:37 AM UTC
L
RZLT - Rezolute to Participate in Upcoming Investor Conferences
RZLT - Rezolute to Participate in Upcoming Investor Conferences
EQUITY | Sep 02, 2026, 11:30 AM UTC